Date:3/16/2010

additional non-GAAP information is intended to provide investors with additional incremental tools for their review of the Company's results and is not meant to be considered in isolation or as a substitute for the actual net income information prepared and provided in accordance with GAAP. The following pro forma adjustments were made solely as supplemental financial information to help investors and the financial community make meaningful comparisons of operating results from one financial period to another. (1) Stock based compensation was removed. (2) The change in the fair market of derivative liabilities was removed. This is the effect of non-cash charges associated with the treatment of the value of certain derivative securities under newly-adopted ASC 815, which effects can vary substantially each quarter along with changes to the price of the underlying common stock during the quarter. (3) Debt discount (non cash) was added back to reflect the actual amount of debt owed at the end of each period reported. (4) Non cash derivative liabilities were removed. (5) All the assets and liabilities of business held for sale were removed. (6) Net income (loss) from discontinued operations was removed. (7) Gain on sale of business unit was removed. (8) The non-cash amortization of the fair market value of warrants issued with the notes and amortized over the term of the notes were removed.

SOURCE Cardium Therapeutics

SOURCE Cardium Therapeutics Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds